Bristol Myers Squibb completed the investment in Abata Therapeutics.

Bristol Myers Squibb, a global biopharmaceutical company, completed the investment in Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases. Financial terms were not disclosed. "Given their leadership in cell therapy, immunology, and neuroscience, we’re honored to have Bristol Myers Squibb as an investor. This investment highlights both the potential of our product engine and a shared belief in the transformational potential of TCR targeted Treg cell therapies for the treatment of autoimmune and inflammatory diseases," Samantha Singer, Abata President and CEO.